| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Phase I Trial of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
elderly |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
advanced non-small cell lung cancer |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
carboplatin |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
pemetrexed |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
maintenance therapy |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Soda, Sayo
Arai, Ryo
Ito, Hiroshi
Uchida, Nobuhiko
Shimizu, Yuka
Koike, Ryosuke
Nakamura, Yusuke
Masawa, Meitetsu
Okutomi, Tomoko
Okutomi, Hiroaki
Morita, Hiroko
Yokoyama, Tatsuya
Watanabe, Taiji
Ikeda, Naoya
Shiobara, Taichi
Hayashi, Yumeko
Funakoshi, Tomoe
Miyoshi, Masaaki
Chibana, Kazuyuki
Takemasa, Akihiro
Shimizu, Yasuo
|
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 著者所属 |
|
|
|
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine |
| 書誌情報 |
Dokkyo Journal of Medical Sciences
巻 46,
号 3,
p. 113-123,
発行日 2019-10-25
|
| 要旨 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Introduction： A phase I trial was conducted to evaluate the feasibility of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy in elderly patients with advanced non-small cell lung cancer （NSCLC）. The primary objective of this study was to determine the maximum tolerated dose （MTD） and the recommended dose （RD） of pemetrexed in combination with carboplatin.
Methods：Chemotherapy-naïve elderly 13 patients （age, ≥70 years） with stage IIIB/IV non-squamous NSCLC were enrolled and received pemetrexed 500 mg/m2 and carboplatin at an area under the curve （AUC）dose of 5 mg/ml/min（level 1）or 6 mg/ml/min （level 2）. Pemetrexed with carboplatin was administered on day 1 of the 21-day cycle. The treatment schedule consisted of four cycles of pemetrexed with carboplatin. Patients who did not have progressive disease after completion of four cycles subsequently received pemetrexed maintenance therapy （500 mg/m2 every three weeks） until disease progression or unacceptable toxicity was noted.
Results：Three patients were enrolled in level 1, in which no dose-limiting toxicity（DLT）was observed. The carboplatin dose was escalated to AUC 6. Two of 3 patients treated in level 2 had grade 4 thrombocytopenia of DLT. MTD was determined as level 2. Consequently, pemetrexed 500 mg/m2 with carboplatin AUC 5 was recommended as the dose for elderly patients with advanced non-squamous NSCLC. An additional 7 patients who received RD showed no DLT. Nine of 13 patients received 4 cycles of combination therapy, and 5 patients were continuously treated with pemetrexed maintenance therapy. Six patients achieved a partial response, and another 6 showed stable disease. The response rate and disease control rate were 46.2％ and 92.3％, respectively. The median progression-free survival for the enrolled patients was 134 days （95％ CI, 95 to 231 days）, and the median overall survival was 346 days （95％ CI, 151 to 549 days）.
Conclusions：The combination therapy of pemetrexed 500 mg/m2 with carboplatin AUC 5 followed by pemetrexed maintenance therapy showed no severe adverse events and was feasible and well-tolerated for elderly patients with advanced non-squamous NSCLC. |
| 記事種別 |
|
|
|
Original |
| 出版者 |
|
|
出版者 |
獨協医学会 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03855023 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00629581 |
DJMS-46-3-Soda-本文 (287.9 kB)
